The Swiss drug avipadil, a synthetic vasoactive in
Post# of 714
(Total Views: 621)
Posted On: 08/08/2020 3:42:51 PM
The Swiss drug avipadil, a synthetic vasoactive intestinal polypeptide, was developed to treat ED. As an ED drug it increases nitric oxide and improves blood flow. The delivery mechanism for this drug for ED was via penile injection. Now that I have every male reader on this board recovering from a cringing ewww response:
NeuroRx an American- Israeli company partnered with Swiss drug maker Relief Therapeutics to develop the modified aviptadil — called RLF-100. The companies are now carrying out two phase 2/3 trials to determine the efficacy of RLF-100 in patients with moderate or severe COVID-19.
The modified drug is being tested using an inhaler delivery to treat CV19. With 300 CV19 patients tested it appears to INHIBIT CV19 replication. Note that NeurRx does NOT claim that it will kill the CV19 virus . On Thursday, the FDA granted “Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 in order to prevent progression to respiratory failure,” the companies said in a press release.
Clinical trials of the inhaled formulation of RLF-100 are expected to begin next month. Relief Therapeutics CEO stated “From an efficacy standpoint we need more data. I would say the probability at the moment stands at 60 to 70 percent that we will get the drug approved," he added.
Selvaraju said trial results could emerge within a "few more months".
https://www.nydailynews.com/coronavirus/ny-co...story.html
https://www.moneycontrol.com/news/world/relie...64021.html
NeuroRx an American- Israeli company partnered with Swiss drug maker Relief Therapeutics to develop the modified aviptadil — called RLF-100. The companies are now carrying out two phase 2/3 trials to determine the efficacy of RLF-100 in patients with moderate or severe COVID-19.
The modified drug is being tested using an inhaler delivery to treat CV19. With 300 CV19 patients tested it appears to INHIBIT CV19 replication. Note that NeurRx does NOT claim that it will kill the CV19 virus . On Thursday, the FDA granted “Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 in order to prevent progression to respiratory failure,” the companies said in a press release.
Clinical trials of the inhaled formulation of RLF-100 are expected to begin next month. Relief Therapeutics CEO stated “From an efficacy standpoint we need more data. I would say the probability at the moment stands at 60 to 70 percent that we will get the drug approved," he added.
Selvaraju said trial results could emerge within a "few more months".
https://www.nydailynews.com/coronavirus/ny-co...story.html
https://www.moneycontrol.com/news/world/relie...64021.html
(1)
(0)Scroll down for more posts ▼